


Technology Advisory Committee C Interests Register

Topic: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy

[ID3892]

Publication Date: 05/10/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Richard Nicholas	Committee member	Direct - financial	Dr Nicholas has attended paid advisory boards with Novartis in an unrelated disease area (MS).	N/A	19.05.2022	N/A	It was agreed his declaration would not prevent Dr Nicholas from participating in discussions of this appraisal.
Emtiyaz Chowdhury	Committee member	Direct – professional and personal	Mr Chowdhury's employer Parexel is a CRO which regularly works with industry to support clinical trials. He has not had any direct involvement or knowledge of any support provided by Parexel to Celgene for this technology.	N/A	02.08.2022	N/A	It was agreed his declaration would not prevent Mr Chowdhury from participating in discussions of this appraisal.
Martin Burr	Patient expert	Indirect - financial	In the last twelve months Mr Burr's nominating organisation Leukaemia Care has received funding from Novartis and Pfizer.	N/A	14.03.2022	N/A	It was agreed his declaration would not prevent Mr Burr from providing expert advice to the committee.



Professor Charles Craddock	Clinical expert	Direct - financial	Professor Craddock has received consultancy, speaker, and advisory fees from Abbvie, Astellas, BMS, Daiichi Sankyo, Eurocept, Janssen, Novartis and Pfizer; research support and speaker fees from Celgene; research support and consultancy fees from Jazz & KITE and consultancy and speaker fees from Roche.	N/A	14.10.2021	N/A	It was agreed his declaration would not prevent Professor Charles Craddock from providing expert advice to the committee.
Dr Manoj Raghavan	Clinical expert	Direct – financial & non-financial	Dr Raghavan has attended advisory boards from Jazz Pharmaceuticals and Pfizer and has held speaker contracts with Astellas Pharmaceuticals and Incyte Biosciences. He is a member of MDS subgroup of NCRI Haemato-oncology CSSG and the UK MDS Forum.	N/A	25.11.2021	N/A	It was agreed his declaration would not prevent Dr Raghavan from providing expert advice to the committee.